Research Progress in Novel Inflammatory Indices in Heart Failure

心力衰竭(Heart failure, HF)是多种心脏及血管疾病共同的主要死亡原因，严重威胁公众健康。随着心脏疾病发病率的增加及人口老龄化程度加深，心力衰竭的患病率和死亡率也不断增加。心衰的发病机制比较复杂，目前研究认为炎症在心血管疾病的发生和发展起着至关重要的作用，引发了广泛的关注和探索，人们发现由血常规中血细胞组合的复合炎症指标，如中性粒细胞/淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、系统免疫炎症指数(SII)等在心力衰竭患者的诊断和预后评估中具有重要价值，且优于单一指标评估。这对未来抗炎治疗及相关药物研发提供了新思路。Heart failure (HF) serves as a major common cause of death across various cardiovascular diseases, posing a serious threat to public health. With the increasing incidence of cardiovascular diseases and the deepening aging population, the prevalence and mortality rate of heart failure continue to rise. The pathogenesis of HF is complex and multifaceted. Current research suggests that inflammation plays a crucial role in the initiation and progression of cardiovascular diseases, which has sparked extensive attention and exploration. Composite inflammatory indices derived from blood cell components in routine blood tests, including the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), are of great value in diagnosis and prognostic assessment of patients with heart failure and are superior to the assessment of a single index. This provides new ideas for future anti-inflammatory treatment and related drug development.